Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
07:00am, Wednesday, 27'th Nov 2024
WARREN, N.J. , Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV
PTC Therapeutics discontinues development of ALS drug after trial failure
04:41pm, Tuesday, 26'th Nov 2024
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
04:30pm, Tuesday, 26'th Nov 2024
- Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J. , Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-con
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 25'th Nov 2024
WARREN, N.J. , Nov. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 20, 2024, the company approved non-statutory stock options to purchase an aggregate of 1
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
06:09pm, Wednesday, 13'th Nov 2024
The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wedn
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
06:02pm, Wednesday, 13'th Nov 2024
- First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and adults - - PTC pioneers new approach for CNS dr
PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript
11:19pm, Thursday, 07'th Nov 2024
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Execu
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
07:30pm, Thursday, 07'th Nov 2024
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall St
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
06:30pm, Thursday, 07'th Nov 2024
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.76 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
04:01pm, Thursday, 07'th Nov 2024
– Strong revenue performance, supporting increase in full-year revenue guidance to $750-800 million – – Regulatory filings for sepiapterin, Translarna™ and AADC gene therapy under review by
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
10:20am, Wednesday, 06'th Nov 2024
Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared duri
PTC Therapeutics to Participate at Upcoming Investor Conferences
04:30pm, Monday, 04'th Nov 2024
WARREN, N.J. , Nov. 4, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: UBS Global Healthcare C
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
07:00am, Wednesday, 30'th Oct 2024
WARREN, N.J. , Oct. 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 25'th Oct 2024
WARREN, N.J. , Oct. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2024, the company approved non-statutory stock options to purchase an aggregate of 1
